Charles Faith L. purchased $34K of ABEO

Charles Faith L. purchased 15,000 shares of ABEONA THERAPEUTICS INC. (ABEO) at $2.29 on 2026-11-13.

Original reporting
SEC EDGAR · Charles Faith L.
Published Nov 16, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ABEO
Neutral
high confidence
Mentioned
$ABEO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABEONeutralLow
01

Why it matters

The director's modest purchase adds a small amount of buying pressure but is unlikely to influence ABEO's stock price significantly.

02

Market read

A routine insider purchase with limited relevance for traders.

03

What to watch

Potential upcoming clinical trial updates that prompted the director's buy.

Relevance 4/10Novelty 4/10Timing: post-market filing on 2026-11-16

Background

SEC Form 4 filing discloses insider transactions. Abeona Therapeutics (ABEO) is a NASDAQ-listed biotech company.

Company-level read

Ticker impact

$ABEONeutralHigh confidence
Context

Director Charles Faith L. bought 15,000 ABEO shares for $34,348.50 on 2026-11-13, raising his holding to 191,407 shares.

Expected impact

minor upward pressure as insider buying signals confidence, but size is too small to move price materially

Evidence & confidence

The transaction is a modest $34K purchase by a director, indicating personal confidence but unlikely to affect broader market sentiment.

Market effects

None; Abeona operates in biotech but the trade is too small to affect sector sentiment.

None; limited to US biotech investors.

None

Counterpoint

The purchase could be a signal of upcoming positive news not yet public.

Key entities

  • Abeona Therapeutics Inc.

    NASDAQ-listed biotech firm developing gene therapies.

  • Charles Faith L.

    Director of Abeona Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Abeona Therapeutics Inc. Q3 2026 Earnings Call Summary

Abeona Therapeutics reported 18% Q3 revenue growth for ZEVASKYN, driven by QTC network expansion. The company acquired ABO-801, a Phase III-ready orphan drug with $750M revenue potential. Manufacturing challenges and FDA timelines were discussed. Abeona expects 85-90% long-term gross margins and strengthened commercial foundation by 2027.

$ABEOMed

What Abeona Therapeutics (ABEO) Said on Its Q3 Earnings Call

Abeona Therapeutics (ABEO) reported Q3 net loss of $4.8M, down from $20.2M in Q2. The company discussed plans for ABO-801, a drug candidate with potential peak revenue of $750M, targeting a Phase III trial with results expected by late 2028. Abeona also announced a $30M private placement and expects sufficient capital for ABO-801's development. The company's cash position was $134.9M as of September.